NCT03608033Phase 3Terminated

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Study sponsor: Omeros Corporation

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-01-12Actual
Enrollment · participants360Actual
Source updated2025-12-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview